“I like to call it the walking pill because it’s made my walking so much better.” - Bambi

Walking Progress Tracker

Track your progress — your personal Walking Progress Tracker

Starting AMPYRA® (dalfampridine) may be a positive step toward potentially improving your walking. Not everyone responds to AMPYRA. Individual results may vary.

This compact Walking Progress Tracker is an easy way to help you monitor your walking, both before and after you start taking AMPYRA. It will help you assess how multiple sclerosis (MS) may affect your walking on a week-by-week basis, and help you identify any changes or improvement you may experience.

You may also find this Progress Tracker useful when you update your healthcare team, so remember to take it with you to your next appointment.

Walking Progress Tracker

AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

IMPORTANT SAFETY INFORMATION

Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.

AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.

Before taking AMPYRA tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.

Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.

Please see the full Prescribing Information and Patient Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AMPYRA®, ACORDA THERAPEUTICS® and the stylized ACORDA THERAPEUTICS® logo are registered trademarks of Acorda Therapeutics, Inc. | AMPYRA® is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland. | AMPYRACONNECT™ is a trademark of Acorda Therapeutics, Inc. | The stylized path logo and the stylized Acorda logo are trademarks of Acorda Therapeutics, Inc. | © 2013 Acorda Therapeutics, Inc. All rights reserved.

AMP2043